Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma
Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1984 |
|---|
| Umfang: |
4 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Cancer chemotherapy and pharmacology - 1978, 12(1984) vom: März, Seite 183-186 |
| Übergeordnetes Werk: |
volume:12 ; year:1984 ; month:03 ; pages:183-186 ; extent:4 |
| Links: |
|---|
| Katalog-ID: |
NLEJ202990753 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ202990753 | ||
| 003 | DE-627 | ||
| 005 | 20230506011322.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1984 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ202990753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma |
| 264 | 1 | |c 1984 | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Bosanquet, Andrew G. |4 oth | |
| 700 | 1 | |a Gilby, Edward D. |4 oth | |
| 773 | 0 | 8 | |i in |t Cancer chemotherapy and pharmacology |d 1978 |g 12(1984) vom: März, Seite 183-186 |w (DE-627)NLEJ188987932 |w (DE-600)1458488-8 |x 1432-0843 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:1984 |g month:03 |g pages:183-186 |g extent:4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF00256542 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 1984 |c 3 |h 183-186 |g 4 | ||
| matchkey_str |
article:14320843:1984----::oprsnfhfdnfsigttsnhasrtoomlh |
|---|---|
| hierarchy_sort_str |
1984 |
| publishDate |
1984 |
| allfields |
(DE-627)NLEJ202990753 DE-627 ger DE-627 rakwb eng Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma 1984 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption. Springer Online Journal Archives 1860-2002 Bosanquet, Andrew G. oth Gilby, Edward D. oth in Cancer chemotherapy and pharmacology 1978 12(1984) vom: März, Seite 183-186 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:12 year:1984 month:03 pages:183-186 extent:4 http://dx.doi.org/10.1007/BF00256542 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 12 1984 3 183-186 4 |
| spelling |
(DE-627)NLEJ202990753 DE-627 ger DE-627 rakwb eng Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma 1984 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption. Springer Online Journal Archives 1860-2002 Bosanquet, Andrew G. oth Gilby, Edward D. oth in Cancer chemotherapy and pharmacology 1978 12(1984) vom: März, Seite 183-186 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:12 year:1984 month:03 pages:183-186 extent:4 http://dx.doi.org/10.1007/BF00256542 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 12 1984 3 183-186 4 |
| allfields_unstemmed |
(DE-627)NLEJ202990753 DE-627 ger DE-627 rakwb eng Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma 1984 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption. Springer Online Journal Archives 1860-2002 Bosanquet, Andrew G. oth Gilby, Edward D. oth in Cancer chemotherapy and pharmacology 1978 12(1984) vom: März, Seite 183-186 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:12 year:1984 month:03 pages:183-186 extent:4 http://dx.doi.org/10.1007/BF00256542 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 12 1984 3 183-186 4 |
| allfieldsGer |
(DE-627)NLEJ202990753 DE-627 ger DE-627 rakwb eng Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma 1984 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption. Springer Online Journal Archives 1860-2002 Bosanquet, Andrew G. oth Gilby, Edward D. oth in Cancer chemotherapy and pharmacology 1978 12(1984) vom: März, Seite 183-186 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:12 year:1984 month:03 pages:183-186 extent:4 http://dx.doi.org/10.1007/BF00256542 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 12 1984 3 183-186 4 |
| allfieldsSound |
(DE-627)NLEJ202990753 DE-627 ger DE-627 rakwb eng Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma 1984 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption. Springer Online Journal Archives 1860-2002 Bosanquet, Andrew G. oth Gilby, Edward D. oth in Cancer chemotherapy and pharmacology 1978 12(1984) vom: März, Seite 183-186 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:12 year:1984 month:03 pages:183-186 extent:4 http://dx.doi.org/10.1007/BF00256542 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 12 1984 3 183-186 4 |
| language |
English |
| source |
in Cancer chemotherapy and pharmacology 12(1984) vom: März, Seite 183-186 volume:12 year:1984 month:03 pages:183-186 extent:4 |
| sourceStr |
in Cancer chemotherapy and pharmacology 12(1984) vom: März, Seite 183-186 volume:12 year:1984 month:03 pages:183-186 extent:4 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Cancer chemotherapy and pharmacology |
| authorswithroles_txt_mv |
Bosanquet, Andrew G. @@oth@@ Gilby, Edward D. @@oth@@ |
| publishDateDaySort_date |
1984-03-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188987932 |
| id |
NLEJ202990753 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202990753</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506011322.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1984 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202990753</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1984</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bosanquet, Andrew G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gilby, Edward D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Cancer chemotherapy and pharmacology</subfield><subfield code="d">1978</subfield><subfield code="g">12(1984) vom: März, Seite 183-186</subfield><subfield code="w">(DE-627)NLEJ188987932</subfield><subfield code="w">(DE-600)1458488-8</subfield><subfield code="x">1432-0843</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:1984</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:183-186</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00256542</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">1984</subfield><subfield code="c">3</subfield><subfield code="h">183-186</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188987932 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-0843 |
| topic_title |
Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a g b ag agb e d g ed edg |
| hierarchy_parent_title |
Cancer chemotherapy and pharmacology |
| hierarchy_parent_id |
NLEJ188987932 |
| hierarchy_top_title |
Cancer chemotherapy and pharmacology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188987932 (DE-600)1458488-8 |
| title |
Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma |
| spellingShingle |
Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma |
| ctrlnum |
(DE-627)NLEJ202990753 |
| title_full |
Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma |
| journal |
Cancer chemotherapy and pharmacology |
| journalStr |
Cancer chemotherapy and pharmacology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1984 |
| contenttype_str_mv |
zzz |
| container_start_page |
183 |
| container_volume |
12 |
| physical |
4 |
| format_se |
Elektronische Aufsätze |
| title_sort |
comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma |
| title_auth |
Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma |
| abstract |
Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption. |
| abstractGer |
Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption. |
| abstract_unstemmed |
Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma |
| url |
http://dx.doi.org/10.1007/BF00256542 |
| remote_bool |
true |
| author2 |
Bosanquet, Andrew G. Gilby, Edward D. |
| author2Str |
Bosanquet, Andrew G. Gilby, Edward D. |
| ppnlink |
NLEJ188987932 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| up_date |
2024-07-06T09:28:50.139Z |
| _version_ |
1803821389068632064 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202990753</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506011322.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1984 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202990753</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1984</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bosanquet, Andrew G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gilby, Edward D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Cancer chemotherapy and pharmacology</subfield><subfield code="d">1978</subfield><subfield code="g">12(1984) vom: März, Seite 183-186</subfield><subfield code="w">(DE-627)NLEJ188987932</subfield><subfield code="w">(DE-600)1458488-8</subfield><subfield code="x">1432-0843</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:1984</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:183-186</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00256542</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">1984</subfield><subfield code="c">3</subfield><subfield code="h">183-186</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| score |
7.4028378 |